3PORRINI P. Can a previous alliance between an acquirer and a target affect acquisition performance? [ J]. J Manage, 2004, 30 (4) :545 -562.
4SAGNER JS. Why working capital drives M&A today[J]. J Corp Account Financ, 2007, 18(2) :41 -45.
5Pfizer financial reports: notes to consolidated financial statements [ R ]. Pfizer Inc, 2002 - 2012.
6LEDFORD H. Blockbuster drug bow outs: pharmaceutical indus- try anxiously struggles to retool as Lipitor patent expires[ J]. Na- ture, 2011, 480:16 - 17.
7ROTH BD. Trans-6-[ 2-(3- or 4-Carboxamido-substituted pyrrol- 1-yl) alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol syn- thesis : USA, 4681893 [ P ]. 1987 - 7 - 21.
8ROTH BD. [ R- ( R * R * ) ] -2- ( 4-fluorophenyl ) -β, δ-dihydroxy- 5- ( 1 -methylethyl-3-phenyl-4- [ ( phenylamino ) carbonyl ] -1H-pyr- role-1-heptanoic acid, its lactone form and salts thereof: USA, 5273995 [ P]. 1993 - 12 - 28.
9BRIGGS CA, HARASAWA K, ICHIKAWA S. Crystalline [R- ( R * , R * ) ] -2-( 4-dfluorophenyl ) -β,δ-dihydroxy-5-( 1-methyle- thyl) -3-phenyl4- [ ( phenylamino ) carbonyl ] -1 H-pyrrole-1-heptanoic acid hemi calcium salt: USA, 5969156[P]. 1999 -10- 19.
10ENCAOUA D, MADIeS T. Dysfunctions of the patent system and their effects on competition [ EB/OL]. (2012 - 10). http:// www. halshs, archives-ouvertes, fr : halshs-00740716.
